drj logo

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
Zip Code*
Please enter a number from 0 to 100.
Strength indicator
I agree to the Terms of Service and Privacy Policy*
Yes, of course I want to receive emails from DRJ!

Already have an account? Log in

drj logo

Welcome to DRJ

Already registered user? Please login here

Login Form

Register
Forgot password? Click here to reset

Create new account
(it's completely free). Subscribe

x
Skip to content
Disaster Recovery Journal
  • EN ESPAÑOL
  • SIGN IN
  • SUBSCRIBE
  • THE JOURNAL
    • Why Subscribe to DRJ
    • Digital Edition
    • Article Submission
    • DRJ Annual Resource Directories
    • Article Archives
    • Career Spotlight
  • EVENTS
    • DRJ Spring 2026
    • DRJ Fall 2026 Call for Presentations
    • DRJ Scholarship
    • Other Industry Events
    • Schedule & Archive
    • Send Your Feedback
  • WEBINARS
    • Upcoming Webinars
    • On Demand
  • MENTOR PROGRAM
  • RESOURCES
    • New to Business Continuity?
    • White Papers
    • DR Rules and Regs
    • Planning Groups
    • DRJ Glossary of Business Continuity Terms
    • Careers
  • ABOUT
    • Advertise with DRJ
    • Board and Committees
      • Executive Council Members
      • Editorial Advisory Board
      • Career Development Committee
      • DEI
      • Glossary Committee
      • Rules and Regulations Committee

Verseon Chooses DataKrypto’s FHEnom for AI to Ensure Continuous Encryption of AI-Driven Medical Research and Clinical Trial Data

by Jon Seals | October 1, 2025 | | 0 comments

BURLINGAME, Calif. – DataKrypto, the creator of the fastest fully homomorphic encryption (FHE) solutions on the market, announced today that Verseon, a drug development innovator, is deploying its cutting-edge FHEnom for AI to ensure the continuous security of AI datasets and proprietary models.

Verseon’s team of scientists, biologists, and medical researchers works diligently to create medicines that improve the world’s treatment of all major human diseases. AI plays a vital role in Verseon’s drug development and clinical trials, and ensuring that highly sensitive data is always protected, throughout AI training and inference, is crucial for maintaining compliance with stringent data privacy regulations.

“DataKrypto’s FHEnom for AI gives us a secure, continuously encrypted solution for our AI training, fine-tuning, and real-world usage,” said David Kita, CSO of Verseon. “With implementation taking just hours, the solution combines security with convenience and speed, allowing us to focus on our core activities.”

“Verseon’s mission-critical drug discovery and development work is reliant on its ability to maintain continuous protection of its clinical trial data and proprietary AI models,” said Ravi Srivatsav, CEO of DataKrypto. “FHEnom for AI fills the encryption gap by enabling AI training and processing without having to decrypt data, which potentially exposes it to malicious use. We are proud to provide the first solution that gives companies like Verseon confidence and peace of mind with their AI implementations, knowing that their data is always secure.”

Building Trust in AI with DataKrypto 

FHEnom for AI is an AI-compliant, zero-knowledge framework that safeguards both customized open-source AI models (adapted for specific enterprise needs) and proprietary models, while ensuring the privacy and protection of sensitive data. It defends against malicious activities, misuse, and adversarial manipulation, securing intellectual property and maintaining the confidentiality of critical datasets. DataKrypto’s solution helps companies deploying AI overcome concerns about data privacy and model security.

For more information about FHEnom for AI, visit https://datakrypto.com/products/.

About Verseon

Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company’s drug programs features multiple novel candidates with unique therapeutic properties. Other current methods can find none of these candidates. Verseon’s rapidly growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancer. The company’s supporters and advisors include multiple Nobel laureates, former heads of R&D at major pharmaceutical companies, and various key opinion leaders in the field of medicine.

About DataKrypto 

DataKrypto reimagines AI security for the enterprise. By combining FHEnom™—the fastest, most scalable Fully Homomorphic Encryption technology available—with Trusted Execution Environments (TEEs), DataKrypto enables organizations to adopt, create, and use AI tools with unmatched security and performance. Every model, every dataset—always encrypted. Even the largest AI systems run securely, with performance intact. DataKrypto empowers organizations to embrace AI, ensuring protection at every step. Learn more at www.datakrypto.com.

Related Content

  1. How Technological Continuity and High Availability Strengthen IT Resilience in Critical Sectors
    How Technological Continuity and High Availability Strengthen IT Resilience in Critical Sectors
  2. Disaster Recovery Journal
    ‘Other Duties As Assigned’
  3. Disaster Recovery Journal
    Glossary

Recent Posts

Maturity Model: How Compliance Drives Data Resilience

February 9, 2026

FirstNet: Built with and for First Responders in Any Winter Storm

February 6, 2026

Cowbell Launches in Australia, Bringing AI-Powered Cyber Protection Backed by the Financial Strength of Zurich

February 6, 2026

Cologix Expands Ashburn Presence With Strategic Land Acquisition, Supporting $5B Long-Term Northern Virginia Growth Plan

February 5, 2026

Cayosoft and XMS Solutions Selected by U.S. Department of War Agency to Modernize ICAM Operations for Mission Resilience

February 5, 2026

Security Experts Struggle to Keep Pace With AI Threats as 90% Report at Least One Security Incident in the Past Year

February 5, 2026

Archives

  • February 2026 (27)
  • January 2026 (61)
  • December 2025 (45)
  • November 2025 (58)
  • October 2025 (78)
  • September 2025 (65)
  • August 2025 (59)
  • July 2025 (70)
  • June 2025 (54)
  • May 2025 (59)
  • April 2025 (91)
  • March 2025 (57)
  • February 2025 (47)
  • January 2025 (73)
  • December 2024 (82)
  • November 2024 (41)
  • October 2024 (87)
  • September 2024 (61)
  • August 2024 (65)
  • July 2024 (48)
  • June 2024 (55)
  • May 2024 (70)
  • April 2024 (79)
  • March 2024 (65)
  • February 2024 (73)
  • January 2024 (66)
  • December 2023 (49)
  • November 2023 (80)
  • October 2023 (67)
  • September 2023 (53)
  • August 2023 (72)
  • July 2023 (45)
  • June 2023 (61)
  • May 2023 (50)
  • April 2023 (60)
  • March 2023 (69)
  • February 2023 (54)
  • January 2023 (71)
  • December 2022 (54)
  • November 2022 (59)
  • October 2022 (66)
  • September 2022 (72)
  • August 2022 (65)
  • July 2022 (66)
  • June 2022 (53)
  • May 2022 (55)
  • April 2022 (60)
  • March 2022 (65)
  • February 2022 (50)
  • January 2022 (46)
  • December 2021 (39)
  • November 2021 (38)
  • October 2021 (39)
  • September 2021 (50)
  • August 2021 (77)
  • July 2021 (63)
  • June 2021 (42)
  • May 2021 (43)
  • April 2021 (50)
  • March 2021 (60)
  • February 2021 (16)
  • January 2021 (554)
  • December 2020 (30)
  • November 2020 (35)
  • October 2020 (48)
  • September 2020 (57)
  • August 2020 (52)
  • July 2020 (40)
  • June 2020 (72)
  • May 2020 (46)
  • April 2020 (59)
  • March 2020 (46)
  • February 2020 (28)
  • January 2020 (36)
  • December 2019 (22)
  • November 2019 (11)
  • October 2019 (36)
  • September 2019 (44)
  • August 2019 (77)
  • July 2019 (117)
  • June 2019 (106)
  • May 2019 (49)
  • April 2019 (47)
  • March 2019 (24)
  • February 2019 (37)
  • January 2019 (12)
  • ARTICLES & NEWS

    • Business Continuity
    • Disaster Recovery
    • Crisis Management & Communications
    • Risk Management
    • Article Archives
    • Industry News

    THE JOURNAL

    • Digital Edition
    • Advertising & Media Kit
    • Submit an Article
    • Career Spotlight

    RESOURCES

    • White Papers
    • Rules & Regulations
    • FAQs
    • Glossary of Terms
    • Industry Groups
    • Business & Resource Directory
    • Business Resilience Decoded
    • Careers

    EVENTS

    • Fall 2025
    • Spring 2026

    WEBINARS

    • Watch Now
    • Upcoming

    CONTACT

    • Article Submission
    • Media Kit
    • Contact Us

    ABOUT DRJ

    Disaster Recovery Journal (DRJ) is the leading resource for business continuity, disaster recovery, crisis management, and risk professionals worldwide. With a global network of more than 138,000 practitioners, DRJ delivers essential insights through two annual conferences, a quarterly digital magazine, weekly webinars, and a rich library of online resources at www.drj.com. Our mission is to empower resilience professionals with the knowledge, tools, and connections they need to protect their organizations in a fast-changing world. Join our community by attending our events, subscribing to our publications, and following us on social media.

    LEARN MORE

    LINKEDIN AND TWITTER

    Disaster Recovery Journal is the leading publication/event covering business continuity/disaster recovery.

    Follow us for daily updates

    LinkedIn

    @drjournal

    Newsletter

    The Journal, right in your inbox.

    Be informed and stay connected by getting the latest in news, events, webinars and whitepapers on Business Continuity and Disaster Recovery.

    Subscribe Now
    Copyright 2026 Disaster Recovery Journal
    • Terms of Use
    • Privacy Policy

    Register to win a Free Pass to DRJ Spring 2026 | The Future Runs on Resilience

    Leave your details below for a chance to win a free pass to DRJ Spring 2026 | The Future Runs on Resilience. The winner will be announced on February 13. Join us for DRJ's 74th Conference!
    Enter Now